Business Description
Biocept Inc
NAICS : 621511
SIC : 8731
ISIN : US09072V4023
Description
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.87 | |||||
| 9-Day RSI | 78.93 | |||||
| 14-Day RSI | 64.08 | |||||
| 12-1 Month Momentum % | -99.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1347.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.17 | |||||
| EV-to-Revenue | 3.66 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| Earnings Yield (Greenblatt) % | -625 | |||||
| FCF Yield % | 7.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIOCQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biocept Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.356 | ||
| EPS (TTM) ($) | -50.9 | ||
| Beta | 238.98 | ||
| Volatility % | 2426.3 | ||
| 14-Day RSI | 64.08 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.00017 | ||
| 12-1 Month Momentum % | -99.83 | ||
| 52-Week Range ($) | 0.0001 - 0.125 | ||
| Shares Outstanding (Mil) | 2.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biocept Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biocept Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biocept Inc Frequently Asked Questions
What is Biocept Inc(BIOCQ)'s stock price today?
The current price of BIOCQ is $0.00. The 52 week high of BIOCQ is $0.13 and 52 week low is $0.00.
When is next earnings date of Biocept Inc(BIOCQ)?
The next earnings date of Biocept Inc(BIOCQ) is 2024-12-03 Est..
Does Biocept Inc(BIOCQ) pay dividends? If so, how much?
Biocept Inc(BIOCQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers